Biogen Net Income 2006-2021 | BIIB

Biogen annual/quarterly net income history and growth rate from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Biogen net income for the quarter ending September 30, 2021 was $0.329B, a 53.07% decline year-over-year.
  • Biogen net income for the twelve months ending September 30, 2021 was $1.546B, a 69.59% decline year-over-year.
  • Biogen annual net income for 2020 was $4.001B, a 32.06% decline from 2019.
  • Biogen annual net income for 2019 was $5.889B, a 32.9% increase from 2018.
  • Biogen annual net income for 2018 was $4.431B, a 74.5% increase from 2017.
Biogen Annual Net Income
(Millions of US $)
2020 $4,001
2019 $5,889
2018 $4,431
2017 $2,539
2016 $3,703
2015 $3,547
2014 $2,935
2013 $1,862
2012 $1,380
2011 $1,234
2010 $1,005
2009 $970
2008 $783
2007 $638
2006 $218
2005 $161
Biogen Quarterly Net Income
(Millions of US $)
2021-09-30 $329
2021-06-30 $449
2021-03-31 $410
2020-12-31 $358
2020-09-30 $702
2020-06-30 $1,542
2020-03-31 $1,399
2019-12-31 $1,440
2019-09-30 $1,546
2019-06-30 $1,494
2019-03-31 $1,409
2018-12-31 $947
2018-09-30 $1,444
2018-06-30 $867
2018-03-31 $1,173
2017-12-31 $-297
2017-09-30 $1,226
2017-06-30 $863
2017-03-31 $748
2016-12-31 $649
2016-09-30 $1,033
2016-06-30 $1,050
2016-03-31 $971
2015-12-31 $832
2015-09-30 $966
2015-06-30 $927
2015-03-31 $823
2014-12-31 $883
2014-09-30 $857
2014-06-30 $715
2014-03-31 $480
2013-12-31 $457
2013-09-30 $488
2013-06-30 $491
2013-03-31 $427
2012-12-31 $292
2012-09-30 $398
2012-06-30 $387
2012-03-31 $303
2011-12-31 $300
2011-09-30 $352
2011-06-30 $288
2011-03-31 $294
2010-12-31 $240
2010-09-30 $254
2010-06-30 $293
2010-03-31 $217
2009-12-31 $306
2009-09-30 $278
2009-06-30 $143
2009-03-31 $244
2008-12-31 $207
2008-09-30 $207
2008-06-30 $207
2008-03-31 $163
2007-12-31 $201
2007-09-30 $119
2007-06-30 $186
2007-03-31 $132
2006-12-31 $109
2006-09-30 $157
2006-06-30 $-171
2006-03-31 $123
2005-12-31 $56
2005-09-30 $27
2005-06-30 $35
2005-03-31 $43
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $32.393B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81